|
|
||||||||
a Stem Cell Biology Laboratory, Large Scale Biology Corporation, Vacaville, California, USA;
b Division of Hematology/Oncology, University of California at Davis Cancer Center, Sacramento, California, USA;
c Jackson Laboratories, Sacramento, California, USA;
d University of California at Davis Medical Center, Department of Pathology, Davis, California, USA
Key Words. Cord blood • SCID-repopulating cells • Ex vivo expansion • Endothelial cells
John P. Chute, M.D., Stem Cell Transplantation Program, Duke University, 2400 Pratt Street, Suite 1100, Durham, North Carolina 27710, USA. Telephone: 919-668-1011; Fax: 919-668-1091; e-mail: johnchute{at}duke.edu
Initial clinical trials examining the transplantation of ex vivo expanded cord blood (CB) cells have failed to demonstrate an impact on hematopoietic recovery compared with historical unmanipulated CB controls. In this study, we tested whether coculture with primary human brain endothelial cells (HUBECs) could increase the engraftment capacity and repopulating cell frequency within CB CD34+ cells. Quantitative analysis demonstrated that HUBEC coculture for 7 days supported a 19-fold greater number of CD34+ cells and 3.4-fold and 2.6-fold greater severe combined immunodeficient (SCID)-repopulating cell (SRC) frequencies than fresh CB CD34+ cells and liquid suspension-cultured cells. Mice transplanted with day-14 HUBEC-cultured cells showed 4.2-fold higher levels of human engraftment than mice transplanted with day-7 HUBEC-cultured cells, indicating that SRC enrichment continued to occur through day 14. Noncontact HUBEC cultures also maintained SRCs at levels comparable with contact HUBEC cultures, demonstrating that HUBEC-secreted soluble factors critically supported SRC self-renewal. Seeding efficiency studies demonstrated that HUBEC-cultured CB CD34+ cells engrafted nonobese diabetic/SCID marrow at significantly higher levels than either fresh CB CD34+ cells or liquid suspension-cultured CD34+ cells. These studies indicate that the application of HUBEC coculture or HUBEC-conditioned media can potentially improve upon current strategies for the clinical expansion of CB stem cells.
This article has been cited by other articles:
![]() |
J. P. Chute, G. G. Muramoto, A. B. Salter, S. K. Meadows, D. W. Rickman, B. Chen, H. A. Himburg, and N. J. Chao Transplantation of vascular endothelial cells mediates the hematopoietic recovery and survival of lethally irradiated mice Blood, March 15, 2007; 109(6): 2365 - 2372. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. P. Chute, G. G. Muramoto, H. K. Dressman, G. Wolfe, N. J. Chao, and S. Lin Molecular Profile and Partial Functional Analysis of Novel Endothelial Cell-Derived Growth Factors that Regulate Hematopoiesis Stem Cells, May 1, 2006; 24(5): 1315 - 1327. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Ando, T. Yahata, T. Sato, H. Miyatake, H. Matsuzawa, M. Oki, H. Miyoshi, T. Tsuji, S. Kato, and T. Hotta Direct evidence for ex vivo expansion of human hematopoietic stem cells Blood, April 15, 2006; 107(8): 3371 - 3377. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Takebe, X. Cheng, A. M. Farese, E. Welty, B. Meisenberg, and T. MacVittie Human Brain Endothelial Cells (HUBEC) Can Expand Both Human Bone Marrow and Cord Blood SCID-Repopulating Cells (SRC) through Cell Contact Rather Than Soluble Factors. Blood (ASH Annual Meeting Abstracts), November 16, 2005; 106(11): 36 - 36. [Abstract] |
||||
![]() |
J. P. Chute, G. G. Muramoto, J. Fung, and C. Oxford Soluble factors elaborated by human brain endothelial cells induce the concomitant expansion of purified human BM CD34+CD38- cells and SCID-repopulating cells Blood, January 15, 2005; 105(2): 576 - 583. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| STEM CELLS | THE ONCOLOGIST | CME | ALPHAMED PRESS JOURNALS |
